Reuters logo
10 天前
BRIEF-Aimmune Therapeutics qtrly net loss per common share, basic and diluted $0.65
2017年8月8日 / 晚上8点27分 / 10 天前

BRIEF-Aimmune Therapeutics qtrly net loss per common share, basic and diluted $0.65

Aug 8 (Reuters) - Aimmune Therapeutics Inc

* Aimmune Therapeutics announces second quarter 2017 financial results

* Qtrly net loss per common share, basic and diluted $0.65

* Aimmune Therapeutics Inc - ‍looking forward to completing our core phase 3 Palisade trial around end of this year; continue to anticipate sharing topline results in Q1 2018​

* Aimmune Therapeutics Inc - ‍cash, cash equivalents, and investments totaled $237.3 million at June 30, 2017, compared to $282.5 million at December 31, 2016​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below